Reply to comment on “Anastrozole (Arimidex ™) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results” by H.T. Mouridsen, H.A. Chaudri-Ross
Reply to comment on “Anastrozole (Arimidex ™) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results” by H.T. Mouridsen, H.A. Chaudri-Ross
Creators - without role
J.-M. Nabholtz - American Hospital of Paris
Publication Details
European journal of cancer (1990), Vol.40(7), pp.1097-1097